Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Date:8/5/2009

share, compared to a net loss of $42.2 million, or $0.96 per share, for the comparable period in 2008. The change in net income (loss) was primarily attributable to a $26.9 million decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $4.4 million decrease in research and development expenses related to KRX-0401, and a $21.1 million increase in license revenue related to an amendment to the September 2007 sublicense agreement with JT/Torii ($18.0 million), as discussed above, and a $3.0 million milestone payment from JT/Torii earned in the first quarter of 2009.

Commenting on the quarter, Ron Bentsur, the Company's Chief Executive Officer, remarked, "Keryx has made significant progress over the last few months. We presented important Phase 2 data on both our compounds, regained full compliance with the listing requirements of the Nasdaq Capital Market, and announced our SPA for the Phase 3 trial of perifosine in multiple myeloma. We look forward to finalizing our discussions with the FDA regarding the U.S. Phase 3 program for Zerenex shortly, at which time Keryx will be in the compelling position of having two Phase 3 compounds." Mr. Bentsur added, "I am excited by the opportunity to transform Keryx into a late-stage development company and maximize shareholder value. On behalf of the entire Keryx team, I want to thank all of our shareholders for their continued support."

On Thursday, August 6, 2009, at 8:30am EDT, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's second quarter financial results and a business outlook for the remainder of 2009.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014  Donald Fresne, President and CEO of Egenix, Inc. ... , PhD to its Scientific Advisory Committee. Dr. ... France , performed research at Embl (European Molecular Biology ... the French institute of health and medical research. He is ... Curie Institute, Orsay, France , and at ...
(Date:9/16/2014)... 16, 2014  The Council for Entrepreneurial Development ... in the country, today released a mid-year update ... It showed that in the first ... startups in the technology, life science, advanced ... from a variety of sources. Significant investment in technology ...
(Date:9/16/2014)... TN (PRWEB) September 16, 2014 ... new initiatives to position themselves for their ... for labeling and encoding, Pharma Packaging Solutions ... new hardware and software and new procedures. ... current Good Manufacturing Practices (cGMP), Pharma Packaging ...
(Date:9/16/2014)... , Sept. 16, 2014  LABSCO, the leading ... products to hospitals, physician office laboratories and alternate ... October 1, 2014, it will serve as Siemens ... market segments and as a semi-exclusive sales distributor ... contiguous United States . LABSCO ...
Breaking Biology Technology:New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3
... Biomerica,Inc. (OTC Bulletin Board: BMRA) has introduced a ... announced that it received CE mark approval to,market and ... in,the European Union. The product will be marketed under ... people in the U.S. are allergic to cat dander,the ...
... 18 Forest Laboratories, Inc.,(NYSE: FRX ) and ... the novel beta,blocker Bystolic(TM) (nebivolol) was approved by the ... hypertension. Bystolic is a once,daily medication that can be ... affects approximately 72 million,adults in the U.S. and 65 ...
... Using the latest methods for nanofabrication, a team led ... electronic property in one of the earliest-known and most-studied ... magnetite. , By changing the voltage in their experiment, ... than minus 250 degrees Fahrenheit to revert from an ...
Cached Biology Technology:Biomerica Introduces a New 15 Minute Home Test for Allergies to Cats and Receives CE Mark Approval for Home Use 2Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 2Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 3Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 4Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 5New property found in ancient mineral lodestone 2
(Date:9/16/2014)... is associated with increased rates and intensity of tobacco ... the relationship between schizophrenia and smoking stems, in part, ... self-medicate symptoms and cognitive impairment associated with the disease. ... of Biological Psychiatry , sheds light on this ... receptors in the brain was lower in schizophrenia patients ...
(Date:9/16/2014)... responsible for practically all vital functions in an ... signals, transport particular substances and control immune system ... do not function independently of each other, but ... the protein networks, you find many similarities with ... TUM,s Chair of Plant Systems Biology. "Some proteins ...
(Date:9/15/2014)... Human skin and gut microbes influence processes from digestion ... are the most biodiverse terrestrial ecosystems on the planet, ... trees in the tropics. Smithsonian scientists and colleagues working ... samples from a single tree were home to more ... from 57 tree species contained more than 7,000 different ...
Breaking Biology News(10 mins):Smoking and schizophrenia linked by alterations in brain nicotine signals 2Good networkers make prime targets 2Smithsonian scientists discover tropical tree microbiome in Panama 2
... study was conducted by researchers from Scripps Research; the ... Taiwan University. It is being published today in the ... Chi-Huey Wong is currently the Ernest W. Hahn Chair ... and directs the Scripps Research lab heading the study. ...
... is your goal, you can't do better than to emulate ... and an unusual pitching stroke that allows the bug to ... is a marvel of engineering. , Z. Jane Wang, professor ... research on flying systems and fluid dynamics today (Feb. 19) ...
... mention the cleaning product industry, repeatedly warn of their ... is raising the intriguing idea that persistent bacterial and ... Robert W. and Vivian K. Cahill Professor in Cancer ... an essay in the Feb. 24 issue of the ...
Cached Biology News:Enzyme inhibitors block replication of SARS virus 2Scientist uses dragonflies to better understand flight 2Scientists look to the Bahamas as a model for coral reef conservation 2Scientists look to the Bahamas as a model for coral reef conservation 3
... The ELx50 is a fast and ... equipped with our patented Dual-ActionTM 16-channel manifold. ... of the dispense and aspiration manifolds for ... 96- and 384-well formats. The problem of ...
... is an automated hybridization system for the ... both the hybridization and post hybridization washing ... single instrument can process up to 12 ... has multi-protocol software, enabling the user to ...
... The S&S Custom Array Service enables scientists ... analysis instrumentation to have FAST Slides printed with ... own library. Processing of the arrays is performed ... Contact S&S to discuss your needs with ...
Acetylcholinesterase (human brain, AChE)...
Biology Products: